18F-FDG PET基线影像组学特征改善弥漫大B细胞淋巴瘤治疗结局预测
影像组学模型AUC为0.76,影像组学联合临床特征模型AUC达0.79,优于IPI模型的0.68;联合模型将阳性预测值提高15%,更准确识别高危患者。
要点
- 基线PET影像组学联合临床特征预测DLBCL治疗结局优于IPI模型。
- 联合模型AUC 0.79,IPI模型AUC 0.68。
- 影像组学使PPV提高15%,2年进展率44% vs 28%。
核心结论
- 使用基线影像组学特征联合现有临床预测因子可识别基线时存在复发风险的患者,并显著改善模型性能。
主要发现
- IPI模型AUC为0.68。
- 最优影像组学模型包含代谢肿瘤体积(MTV)、SUVpeak的自然对数及最大病灶与任何其他病灶间的最大距离(Dmaxbulk),AUC为0.76。
- 联合肿瘤相关参数(MTV、SUVpeak、Dmaxbulk)与患者相关参数(WHO体能状态、年龄>60岁)的模型表现最佳,AUC为0.79。
- 影像组学特征加入临床预测因子使阳性预测值提高15%,相比IPI模型更准确选择高危患者(2年TTP进展率44% vs 28%)。
关键数值与推荐
- 病灶勾画采用标准化摄取值≥4.0的半自动分割方法。
- 高危组基于事件发生率定义,诊断性能用阳性和阴性预测值评估。
临床怎么用
- 在基线18F-FDG PET中提取MTV、SUVpeak和Dmaxbulk等影像组学特征,联合WHO体能状态和年龄>60岁,可辅助识别一线治疗后高进展风险的DLBCL患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Accurate prognostic markers are urgently needed to identify diffuse large B-Cell lymphoma (DLBCL) patients at high risk of progression or relapse. Our purpose was to investigate the potential added value of baseline radiomics features to the international prognostic index (IPI) in predicting outcome after first-line treatment. METHODS: Three hundred seventeen newly diagnosed DLBCL patients were included. Lesions were delineated using a semi-automated segmentation method (standardized uptake value ≥ 4.0), and 490 radiomics features were extracted. We used logistic regression with backward feature selection to predict 2-year time to progression (TTP). The area under the curve (AUC) of the receiver operator characteristic curve was calculated to assess model performance. High-risk groups were defined based on prevalence of events; diagnostic performance was assessed using positive and negative predictive values. RESULTS: The IPI model yielded an AUC of 0.68. The optimal radiomics model comprised the natural logarithms of metabolic tumor volume (MTV) and of SUVpeak and the maximal distance between the largest lesion and any other lesion (Dmaxbulk, AUC 0.76). Combining radiomics and clinical features showed that a combination of tumor- (MTV, SUVpeak and Dmaxbulk) and patient-related parameters (WHO performance status and age > 60 years) performed best (AUC 0.79). Adding radiomics features to clinical predictors increased PPV with 15%, with more accurate selection of high-risk patients compared to the IPI model (progression at 2-year TTP, 44% vs 28%, respectively). CONCLUSION: Prediction models using baseline radiomics combined with currently used clinical predictors identify patients at risk of relapse at baseline and significantly improved model performance. TRIAL REGISTRATION NUMBER AND DATE: EudraCT: 2006-005,174-42, 01-08-2008.
引用
- Eertink JJ, van de Brug T, Wiegers SE, et al. 18F-FDG PET baseline radiomics features improve the prediction of treatment outcome in diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2021. PMID: 34405277. doi:10.1007/s00259-021-05480-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。